With the FDA approval for cosmetic use, Xeomin now joins the ranks of BOTOX® Cosmetic to reduce frown lines as well as wrinkles around the eyes and forehead. Worldwide, more than 84,000 people have been treated with Xeomin injections. The U.S. is actually the 20th country to approve this drug. This Botox alternative was already approved for use in adults with cervical dystonia and blepharospasm. Cervical dystonia is characterized by abnormal neck pain and movements, and blepharospasm is marked by abnormal, involuntary blinking or spasm of the eyelids.
Xeomin (IncobotulinumtoxinA) is made from the bacteria that causes botulism. Botulinum toxin blocks nerve activity in the muscles, causing a temporary reduction in muscle activity.
Is Xeomin Better or Worse Than BOTOX®?
Unlike its predecessors, Xeomin does not need to be refrigerated. This is often an advantage when it comes to distribution. What’s more, Xeomin is “naked”. There are no additives — just botulinum toxin type A. This may lessen a patient’s likelihood of developing antibodies to Xeomin. When your body senses a foreign invader, it responds by creating antibodies and launching an attack. If this were to occur with a neurotoxin such as botulinum toxin type A, it may not have its desired effects.
What are the risks?
There is a risk that all botulinum toxin products may spread from the area where they were injected to other parts of the body, causing potentially life-threatening swallowing and breathing problems. This was predominantly seen in children treated with Botox off-label for cerebral palsy. These issues have not been reported among people who received botulinum products for cosmetic uses or to treat blepharospasm.
Other risks may include:
- Bruising at the injection site
- Allergic reactions such as itching, swelling or shortness of breath